Apr 17 |
Alterity Therapeutics Parkinson’s Disease and Multiple System Atrophy Data Featured at the American Academy of Neurology (AAN) 2024 Annual Meeting
|
Apr 10 |
Alterity Therapeutics to Present New Data on ATH434 at the World Orphan Drug Congress USA 2024
|
Mar 26 |
Alterity Therapeutics Receives a A$3.9 Million Research & Development Tax Incentive Refund
|
Feb 20 |
Alterity Therapeutics to Present New Data at the Upcoming American Academy of Neurology 2024 Annual Meeting
|
Feb 6 |
Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Second Review
|
Jan 29 |
Alterity Therapeutics to Participate in the ShareCafe Hidden Gems Webinar This Week
|
Jan 22 |
Alterity Therapeutics Issues Shareholder Letter Highlighting Pipeline Advances and Key Upcoming Milestones
|
Dec 21 |
Alterity Therapeutics Appoints Phillip Hains as Chief Financial Officer
|
Dec 5 |
Alterity (ATHE) Up on Preclinical Parkinson's Treatment Data
|
Dec 4 |
Alterity Therapeutics to Host Webcast to Discuss ATH434 Efficacy Data in Primates and Recent Clinical Progress
|